Understanding how heart failure with preserved ejection fraction is influenced by genetics and metabolism
Epigenetic Regulation of Heart Failure with Preserved Ejection Fraction
This study is looking at heart failure with preserved ejection fraction (HFpEF), which affects many people, especially those who are overweight or have high blood pressure, to see how changes in genes and metabolism in different organs might lead to this condition, and it hopes to find new ways to improve heart health using existing medications.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11130807 on NIH RePORTER |
What this research studies
This research investigates heart failure with preserved ejection fraction (HFpEF), a condition affecting millions of Americans, particularly those with obesity and hypertension. The study aims to explore how changes in gene regulation and metabolism across different organs contribute to the development of HFpEF. By using animal models, the researchers will examine the effects of existing medications that target multiple organ systems, potentially leading to new treatment strategies. Patients may benefit from insights gained about how these therapies can improve heart function and overall health.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with heart failure with preserved ejection fraction, particularly those who are also dealing with obesity or hypertension.
Not a fit: Patients with heart failure of other types or those without obesity or hypertension may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve heart function and quality of life for patients with HFpEF.
How similar studies have performed: Previous research has shown promising results with similar therapeutic approaches in other forms of heart disease, suggesting potential for success in this area as well.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Vondriska, Thomas M. — University of California Los Angeles
- Study coordinator: Vondriska, Thomas M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.